Grifols, S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRFS research report →
Price Chart
About the company
Grifols, S. A. , a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma.
- CEO
- Jose Ignacio Abia Buenache
- IPO
- 2011
- Employees
- 25,258
- HQ
- Barcelona, CT, ES
Get TickerSpark's AI analysis on GRFS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.89B
- P/E
- 15.15
- Fwd P/E
- 9.34
- PEG
- 0.49
- P/S
- 0.89
- P/B
- 1.28
- EV/EBITDA
- 8.65
- Div Yield
- 0.76%
- Gross Margin
- 37.10%
- Op Margin
- 16.42%
- Net Margin
- 6.41%
- ROE
- 8.83%
- ROIC
- 5.50%
Latest fiscal year · YoY change
- Revenue
- $7.23B+0.2%
- Gross Profit
- $2.58B-7.7%
- Op Income
- $1.19B
- Net Income
- $386.13M+146.1%
- EPS
- $0.57+147.8%
- OCF Growth
- +11.5%
- FCF Growth
- +41.5%
- 52W High
- $9.77
- 52W Low
- $6.96
- 50D MA
- $7.82
- 200D MA
- $7.95
- Beta
- 1.19
- RSI (14)
- 47
- Avg Volume
- 628.64K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Grifols delivered stronger Q3 growth, margin expansion and cash generation, while management said full-year 2026 guidance remains on track despite continued China albumin weakness.· November 2, 2026
- Q3 group revenue rose 8.4% at constant currency to EUR 2.04 billion, with adjusted EBITDA of EUR 538 million and a 26.4% margin.
- Biopharma drove the quarter, led by IG growth of 11.3% and subcutaneous IG growth of 40.3%, while Alpha-1 and Specialty Proteins also posted a very strong quarter.
- Albumin remained the main drag, falling 13.2% in Q3 and 13.9% year to date at constant currency, with China inventories and regulation still pressuring sales.
- Free cash flow before M&A reached EUR 298 million in the first nine months, and net leverage declined to 3.98x.
- Management reiterated full-year 2026 adjusted EBITDA margin guidance of 25% and said it remains confident in free cash flow guidance and longer-term targets.
Group net revenues were EUR 2.04 billion in Q3 and EUR 5.614 billion for the first nine months, up 8.4% and 4.6% respectively at constant currency. Adjusted EBITDA was EUR 538 million in Q3 and EUR 1.392 billion for the first nine months, up 9.8% and 5% year over year, with margins of 26.4% in Q3 and 24.8% year to date. Reported gross margin was 39.6% in Q3 and 38% for the first nine months; group profit rose 28.4% year over year to EUR 390 million. Free cash flow before M&A was EUR 298 million for the first nine months, up 59% or EUR 110 million year over year, and total net leverage stood at 3.98x with liquidity of EUR 2.14 billion. For the full year, management reaffirmed a 25% adjusted EBITDA margin target and said Q4 sales should be modestly above Q4 2025, with IG also expected to reflect that tougher comparison. They also reiterated confidence in the full-year free cash flow guidance and the 2027 target range.
Nacho Abia emphasized that the quarter showed the company’s strategy working together: core franchise growth, better profitability, stronger cash conversion and lower leverage. He repeatedly pointed to Biopharma strength, especially IG and subcutaneous IG, plus improving contributions from Alpha-1 and Specialty Proteins, as evidence of a more resilient portfolio. His tone was constructive but measured, especially on albumin, where he said China normalization is taking longer than expected and the company is focusing on disciplined execution rather than a quick rebound.
Rahul Srinivasan focused on operating leverage and balance-sheet progress. He said the improvement in financial performance anticipated on prior calls is materializing, cited 60 basis points of gross margin expansion in Q3 to 39.6%, and noted adjusted EBITDA margin expansion to 26.4% in the quarter and 24.8% year to date. He highlighted EUR 298 million of free cash flow before M&A, total net leverage of 3.98x, secured net leverage of 2.5x, and liquidity of EUR 2.14 billion. He also said the company redeemed EUR 500 million of its most expensive debt earlier this year, expects cash interest costs to be in line with 2025, and said any possible noncore R&D impairment review would be noncash and would not affect adjusted EBITDA, free cash flow or credit agreement leverage.
Analysts pressed management on Q4 phasing, IG growth after a strong Q3, albumin destocking in China, free cash flow upside, R&D capitalization, Diagnostics trends, SPARTA expectations, the U.S. Biopharma IPO timing, Egypt ramp-up and regulatory scrutiny. Management said Q4 sales should be only modestly above Q4 2025 and that IG should also face that tougher comparison; on albumin, Abia said sell-through is improving but inventories remain high and normalization may take until 2027. They confirmed the R&D shift was partly due to capitalizing Mundaka after milestones were met, explained Diagnostics growth came from blood typing and NAT offsetting the QuidelOrtho runoff, and said the IPO review is still under Board assessment with no update expected until 2027. On regulatory scrutiny, Abia said agency attention is industry-wide and tied to patient safety, not specific to Grifols.
The call showed broad-based improvement in the company’s core economics: stronger Biopharma demand, higher adjusted EBITDA, expanding margins and materially better free cash flow. Management also sounded confident that Egypt is becoming a strategic sourcing and margin lever, with more collections, more centers and greater benefit expected in 2027 and beyond.
Albumin remains the clearest risk, with China destocking and regulatory pressure taking longer to normalize than management previously hoped. Q4 is expected to be only modestly better than a strong comparison quarter, Diagnostics will continue to reflect the QuidelOrtho runoff through 2026, and the U.S. Biopharma IPO remains uncertain and not likely to be updated until 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.7%
- Shares Outstanding
- 845.97M
- Float Shares
- 834.63M
of shares held by institutions
174 13F filers
Congressional trading
Senate and House stock disclosures for GRFS, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Brandes Investment Partners, LP | 38.31M | ▲ 490.75K |
| Capital World Investors | 22.91M | 0 |
| Permian Investment Partners, LP | 17.76M | ▼ 1.98M |
| Bank Of America Corp | 8.28M | ▲ 1.73M |
| Black Creek Investment Management Inc. | 6.41M | ▼ 1.27M |
| Millennium Management LLC | 3.97M | ▼ 401.78K |
| Flat Footed LLC | 3.55M | ▼ 802.54K |
| Janus Henderson Group Ltd. | 3.20M | ▲ 3.20M |
| Jupiter Topco LLC | 2.96M | ▲ 2.96M |
| Arrowstreet Capital, Limited Partnership | 2.90M | ▲ 248.54K |
| Armistice Capital, LLC | 2.74M | ▼ 200.00K |
| New York State Common Retirement Fund | 2.45M | 0 |
Held by 26 ETFs
Biggest fund positions in GRFS by dollar value.
Our GRFS coverage
Recent articles, reports, and earnings notes.
No research on GRFS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GRFS report →Grifols: Plasma, Profits, And Recovery Gathering Momentum
seekingalpha.com · Nov 3
Grifols, S.A. (GIKLY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 2
Grifols Q3 Earnings Call Highlights
marketbeat.com · Nov 2
Grifols, S.A. (NASDAQ:GRFS) Sees Significant Increase in Short Interest
defenseworld.net · Oct 16
Head to Head Analysis: Creative Medical Technology (NASDAQ:CELZ) versus Grifols (NASDAQ:GRFS)
defenseworld.net · Sep 30
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
zacks.com · Sep 24
Grifols says Canada plasma license suspension has no impact
reuters.com · Sep 24
Grifols: Better Plasma Economics Can Unlock A Discounted Equity
seekingalpha.com · Sep 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.